biote Corp(BTMD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 5:25 PM ET (Korea 9/12 06:25)
Full metrics table
| Index | - | P/E | 11.05 | EPS (ttm) | 0.12 | Insider Own | 17.02% | Shs Outstand | 27.7M | Perf Week | -14.19% |
| Market Cap | 0.05B | Forward P/E | 5.6 | EPS next Y | 763.64% | Insider Trans | 2.21% | Shs Float | 23.8M | Perf Month | -6.34% |
| Enterprise Value | 0.17B | PEG | - | EPS next Q | -0.01 | Inst Own | 62.78% | Short Float | 5.86% | Perf Quarter | -45.27% |
| Income | 0.01B | P/S | 0.26 | EPS this Y | -96.28% | Inst Trans | -8.46% | Short Ratio | 4.36 | Perf Half Y | -13.64% |
| Sales | 0.18B | P/B | - | EPS next 5Y | -12.25% | ROA | 5.67% | Short Interest | 1.40M | Perf YTD | -48.85% |
| Book/sh | -2.38 | P/C | 4.28 | EPS past 3/5Y | - 11.37% | ROE | - | 52W High | -62.38% ($3.54) | Perf Year | -60.53% |
| Cash/sh | 0.31 | P/FCF | 2.4 | Sales past 3/5Y | 5.23% 10.52% | ROIC | 9.92% | 52W Low | 4.72% ($1.27) | Perf 3Y | -72.91% |
| Dividend Est. | - | EV/EBITDA | 6.67 | EPS Y/Y TTM | -82.99% | Gross Margin | 66.93% | Volatility(W/M) | 8.63% 9.01% | Perf 5Y | -86.19% |
| Dividend TTM | - | EV/Sales | 0.94 | Sales Y/Y TTM | -7.81% | Oper. Margin | 12.03% | ATR (14) | 0.14 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.81 | EPS Q/Q | -328.61% | Profit Margin | 3.19% | RSI (14) | 34.58 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.43 | Sales Q/Q | -9.48% | SMA20 | -11.88% ($1.51) | Beta | 1.69 | Target Price | $2.61 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/5 | SMA50 | -29.36% ($1.88) | Rel Volume | 0.43 | Prev Close | $1.31 |
| Employees | 223 | LT Debt/Eq | - | EPS/Sales Surpr. | -961.42% -4.17% | SMA200 | -35.97% ($2.08) | Avg Volume(3M) | 0.32M | Price | $1.33 |
| IPO | 2021/4/28 | Option/Short | No/Yes | Trades | 550 | Volume | 138,438 | Change | 1.53% |
Company
BTMD is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 This is a US healthcare company that supplies hormone balance management pellet procedures and related nutritional supplements to a network of medical professionals. Founded in 2011 by Gary Donovitz, the company operates a business model that bundles products, education, and practice expansion support to enable its affiliated medical practitioners to offer pellet procedures to their patients.
Over the past 1 year, on the lower side
62% below its 1-year high.
BTMD makes money exceptionally well
12.03% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -96.3% this year.
Tap to view numbers
The price looks about right
Trading at 11.1 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -72.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 62.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IVSS 0.00%
IWC 0.00%
FLQS 0.00%
HDG 0.00%
HONG 0.00%It ranks #4 in the industry
Based on market cap of $48M.
BTMD $48M PER 11.1
HCA $92B PER 14.3
THC $21B PER 10.2
EHC $12B PER 19.8
FAQ
What kind of company is BTMD?
BTMD belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of BTMD?
The market cap of BTMD is approximately $48M, ranking 4,959 within its sector.
What is the P/E ratio of BTMD?
BTMD has a P/E ratio of approximately 11.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for BTMD?
BTMD has recorded a 52-week high of $3.54 and a low of $1.27.
